Tempus AI (TEM) Set to Release Earnings on Monday

Tempus AI (NASDAQ:TEM) is projected to post its Q3 2026 results after the market closes on Monday, November 2nd. Analysts expect Tempus AI to post earnings of ($0.0808) per share and revenue of $409.39 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Monday, November 2, 2026 at 8:45 AM ET.

Tempus AI (NASDAQ:TEM) last issued its earnings results on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10. The company had revenue of $382.49 million during the quarter, compared to the consensus estimate of $379.69 million. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%. Tempus AI’s quarterly revenue was up 21.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.22) earnings per share. On average, analysts expect Tempus AI to post ($1.43) EPS for the current fiscal year and ($1.13) EPS for the next fiscal year.

Tempus AI Stock Down 0.0%

NASDAQ:TEM opened at $67.61 on Monday. The firm has a market capitalization of $12.20 billion, a PE ratio of -46.95 and a beta of 3.54. The stock has a 50 day moving average of $69.24 and a 200-day moving average of $57.26. Tempus AI has a 52 week low of $40.77 and a 52 week high of $93.38. The company has a current ratio of 3.30, a quick ratio of 3.16 and a debt-to-equity ratio of 3.06.

Key Headlines Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Needham reiterates Buy rating: Needham & Company maintained its Buy recommendation and set a $75 price target, implying roughly 11% upside from the cited share price. The call reinforces Wall Street support for Tempus’ growth outlook. Needham analyst recommendations
• Positive Sentiment: Expanded Bristol Myers Squibb relationship: Tempus announced multi-year oncology and AI-data agreements with Bristol Myers Squibb, a major pharmaceutical validation of its clinical-data platform. The collaboration could support recurring data-related revenue and increase Tempus’ role in drug development. Tempus expands Bristol Myers partnership
• Positive Sentiment: New Pathos AI partnership expands neuroscience reach: Tempus is partnering with Pathos AI and Bristol Myers Squibb on medical research, including neurology and neuroscience applications. Pathos’ $237 million financing and approximately $3 billion valuation may increase the visibility and perceived strategic value of Tempus’ data and AI capabilities. Tempus expands neurology data partnership
• Positive Sentiment: Investor commentary remains constructive: Recent analyses describe Tempus as less risky than previously viewed and highlight its proprietary healthcare-data advantage, as well as its involvement with Moderna’s cancer-vaccine efforts. These opinions add momentum, although they are not company financial results. Tempus AI less risky analysis
• Neutral Sentiment: Tempus remains unprofitable and carries elevated volatility, so investors will likely focus on whether these partnerships translate into sustained revenue growth and improved margins. The company’s recent quarterly results showed stronger-than-expected revenue and a narrower-than-expected loss, but execution remains important.

Insider Buying and Selling

In other news, Director Nadja West sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $69.00, for a total transaction of $207,000.00. Following the completion of the transaction, the director directly owned 31,981 shares in the company, valued at approximately $2,206,689. The trade was a 8.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Andrew Polovin sold 2,951 shares of the business’s stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $75.00, for a total value of $221,325.00. Following the transaction, the executive vice president owned 135,189 shares of the company’s stock, valued at approximately $10,139,175. This represents a 2.14% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,280,965 shares of company stock valued at $80,397,564 in the last ninety days. Insiders own 24.26% of the company’s stock.

Analyst Upgrades and Downgrades

TEM has been the topic of several recent research reports. The Goldman Sachs Group assumed coverage on Tempus AI in a report on Monday, September 21st. They issued a “neutral” rating and a $75.00 price target on the stock. Wall Street Zen upgraded Tempus AI from a “sell” rating to a “hold” rating in a research note on Saturday, July 25th. BTIG Research increased their target price on Tempus AI from $70.00 to $80.00 and gave the stock a “buy” rating in a research report on Thursday, August 20th. Lake Street Capital lowered Tempus AI to a “hold” rating in a research report on Monday, July 20th. Finally, Guggenheim raised their target price on Tempus AI from $65.00 to $92.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Eleven investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Tempus AI has an average rating of “Hold” and a consensus target price of $72.37.

About Tempus AI

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.